Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Ignatiadis M, Bailey A, McArthur H, El-abed S, de Azambuja E, Metzger O, Chui S, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger G, Jassem J, Lee S, Higgins M, Zarba J, Schmidt M, Gomez H, Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch N, Bajetta E, Ohno S, Im S, Werutsky G, Gal-Yam E, Farre X, Tseng L, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron D, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA 2025, 333: 1150-1160. PMID: 39883436, PMCID: PMC11783246, DOI: 10.1001/jama.2024.26886.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerAdverse eventsEarly-stage triple-negative breast cancerInvasive disease-free survival eventsTriple-negative breast cancer subtypeDisease-free survival hazard ratioInvasive disease-free survivalTreatment-related grade 3Disease-free survival eventsRandomized phase 3 trialIncidence of fatal adverse eventsRisk of recurrent diseaseIndependent data monitoring committeeAtezolizumab to chemotherapyDisease-free survivalNon-Hispanic black womenSurvival hazard ratioBreast cancer subtypesPhase 3 trialFatal adverse eventsPatient follow-upAdjuvant atezolizumabPostsurgery chemotherapyStandard chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply